AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17434899
Drug: Docetaxel 70
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 70 mg/m² on day 2 plus oral estramustine 280 mg twice daily on days 1-5 (DE)
Trial: 17434899
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² on day 1 (D)
Trial: 12927020
Drug: Ascorbate (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbate (1000 mg daily)
Trial: 11820041
Drug: Intensive intravenous
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intravenous insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg/dl)
Trial: 11820041
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg/dl and maintenance of glucose at a level between 180 and 200 mg/dl)
Trial: 9623009
Drug: Intravenous famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous famotidine
Trial: 9623009
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no H2 blockers)
Trial: 31026419
Drug: Submucosal injection
RxNorm normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection of tramadol
Trial: 31026419
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injection (control)
Trial: 17010738
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg/week
Trial: 12705296
Drug: Immediate placement
RxNorm normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate placement of titanium dental implants (Im)
Trial: 12705296
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of titanium dental implants (De)
Trial: 10944563
Drug: Racecadotril (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril (1.5 mg/kg orally every eight hours)
Trial: 7047173
Drug: Penbutolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (mean dose 83 +/- 19 mg)
Trial: 7047173
Drug: Penbutolol (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (same dose as above)
Trial: 31850777
Drug: Conventional buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional buccal infiltration by metallic aspirating syringe
Trial: 31850777
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration by computer‐controlled local anaesthetic device (Wand STA)
Trial: 27454528
Drug: PDT (Photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT (Photodynamic Therapy with curcumin and blue light)
Trial: 27454528
Drug: PDT +
RxNorm normalized name: Photodynamic Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT + S (Photodynamic Therapy with curcumin, surfactant SDS, and blue light)
Trial: 27454528
Drug: Chlorhex (Chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhex (Chlorhexidine treatment)
Trial: 24852116
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus cetuximab (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² with cetuximab 500 mg/m²)
Trial: 24852116
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m²)
Trial: 22995673
Drug: LI85008F formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI85008F formulation (900 mg/day in three divided doses)
Trial: 22995673
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three identical capsules)
Trial: 9699761
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin and gentamicin
Trial: 7794701
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg at bedtime
Trial: 2927449
Drug: Lumpectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumpectomy with radiation and adjuvant chemotherapy
Trial: 26273138
Drug: Preoperative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Trial: 26273138
Drug: Preoperative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 100 mg flurbiprofen axetil by PCA pump
Trial: 26273138
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL placebo and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Trial: 26273138
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative administration of flurbiprofen axetil
Trial: 23732551
Drug: MedDiet supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedDiet supplemented with extra-virgin olive oil (EVOO) 1 l/week
Trial: 23732551
Drug: MedDiet supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedDiet supplemented with mixed nuts 30 g/day
Trial: 21690287
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir (infused concurrently with oral oseltamivir)
Trial: 21690287
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir
Trial: 17116006
Drug: Lipid-lowering drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs (9% of subjects in 2004)
Trial: 17116006
Drug: Population without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Population without lipid-lowering drugs
Trial: 17116006
Drug: Population achieving
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population achieving cholesterol levels below 5.0 mmol L(‐1) in 2004
Trial: 9303254
Drug: Regular Treatment
RxNorm normalized name: Midol Regular
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Treatment Group
Trial: 18029476
Drug: 1.1 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 g/d eicosapentanoic acid (EPA) + docosahexanoic acid (DHA) for 6 weeks
Trial: 15664094
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Trial: 15664094
Drug: saline continuously
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Trial: 7607280
Drug: Recombinant Human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Human Interferon Gamma (rIFN-gamma) administered subcutaneously three times weekly at a dose of 0.05 mg per m2
Trial: 2213948
Drug: Antibiotics (cefazolin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefazolin, one dose before procedure and then q 6 h until tube removal)
Trial: 975489
Drug: ICI 74,917
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 74,917 administered from a pressurized aerosol
Trial: 16554455
Drug: Intranasal ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal ciclesonide (800 microg/d)
Trial: 10722136
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month into treatment
Trial: 10722136
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 1 week after treatment cessation
Trial: 1444522
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K1 (1 mg)
Trial: 1444522
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and intramuscular)
Trial: 30851653
Drug: Gradual exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual exposure (EXP-G; n = 19)
Trial: 29428960
Drug: Curcuma aeruginosa
RxNorm normalized name: CURCUMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma aeruginosa extract (CA-ext) applied twice daily via roll-on applicators
Trial: 29428960
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion applied twice daily via roll-on applicators
Trial: 25332466
Drug: Biofortified beans
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofortified beans (8.8 mg Fe, 1320 mg PA/100 g)
Trial: 25332466
Drug: Control beans
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control beans (5.4 mg Fe, 980 mg PA/100 g)
Trial: 16602668
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg continuous daily therapy
Trial: 16602668
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg on-demand treatment
Trial: 9336333
Drug: Indomethacin (0.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.66 mg/kg)
Trial: 9336333
Drug: Indomethacin (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0, 0.17, 0.33, 0.66 and 1.33 mg/kg) with ethanol (0 and 1 g/kg)
Trial: 9336333
Drug: Indomethacin (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0 and 0.66 mg/kg) with pentobarbital (0, 1.33 and 4 mg/kg)
Trial: 1337362
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of total dietary fiber as modified guar gum
Trial: 1337362
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of total dietary fiber as soy polysaccharide
Trial: 1337362
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of fiber (maltodextrin)
Trial: 25233346
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid emulsion (ABLE) 15 mg/kg single infusion
Trial: 25233346
Drug: Liposomal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal formulation (LAmB)
Trial: 21164548
Drug: NUTRIOSE supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE supplementation (17 g twice daily for 12 weeks)
Trial: 8935341
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day of terbinafine for 3 months
Trial: 8935341
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months
Trial: 29801474
Drug: HF10 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF10 injection every 2 weeks for up to 4 times
Trial: 24149930
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G‐GR) 600 mg am/1,200 mg pm
Trial: 24149930
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G‐GR)
Trial: 22215656
Drug: BicaVera solution
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BicaVera solution (bicarbonate/low-GDP PD solution)
Trial: 22215656
Drug: BicaVera solution
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BicaVera solution
Trial: 16275807
Drug: D-serine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (2 g/d)
Trial: 18036483
Drug: Randomized controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized controlled treatment trials
Trial: 15759147
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of radioiodide
Trial: 15759147
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of radioiodide
Trial: 10606875
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg b.w. IVIg (group A)
Trial: 10606875
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg b.w. IVIg (group B)
Trial: 10606875
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g IVIg/kg b.w. (for initial non-responders in group A)
Trial: 10606875
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IVIg/kg b.w. (for initial non-responders in group B)
Trial: 28158151
Drug: 0.625% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625% capsaicin patch (CP)
Trial: 28158151
Drug: Repetitive patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive patch application (0.625% CP and 0.075% capsaicin cream)
Trial: 18304334
Drug: Peer mentor
RxNorm normalized name: Mentol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peer mentor support (two-weekly contact tailored to individual needs)
Trial: 10741298
Drug: Epirubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 40 mg/m2 intravenous push, Docetaxel 75 mg/m2 in 1 h infusion, Cisplatin 75 mg/m2 with pre‐ and posthydration, treatment repeated every 21 days
Trial: 9095231
Drug: Conventional immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunotherapy with natural pollen extract
Trial: 1396370
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray (80-120 mg)
Trial: 29360915
Drug: eGFR decline
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR decline below cohort median (-1.28 ml/minute/1.73 m2/2 years)
Trial: 29360915
Drug: 5 ml/min/1.73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/min/1.73 m2/year eGFR decline
Trial: 25898077
Drug: Health-promoting programme
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-promoting programme implemented in treatment schools
Trial: 20186629
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue perfusion via superior rectal artery
Trial: 18467721
Drug: Extended-dose temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended-dose temozolomide (TMZ) 75 mg/m²/d for 6 weeks followed by a 2-week rest period
Trial: 11535970
Drug: Neltenexine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neltenexine (1 sachet thrice daily for 20 days)
Trial: 11535970
Drug: Sobrerol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sobrerol (1 sachet thrice daily for 20 days)
Trial: 9489902
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 1 week
Trial: 7530124
Drug: Drug-induced changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced changes
Trial: 27973684
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injection (sodium hyaluronate)
Trial: 27973684
Drug: Arthrocentesis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis with 0.9% NaCl solution (SS)
Trial: 21438989
Drug: Topiramate (96-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (96-200 mg/day)
Trial: 11703422
Drug: Miglitol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (25 mg t.i.d. for 4 weeks, 50 mg t.i.d. for 12 weeks, 100 mg t.i.d. for 16 weeks)
Trial: 11703422
Drug: Miglitol combined
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol combined with metformin
Trial: 11703422
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with metformin
Trial: 11703422
Drug: Miglitol/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol/metformin
Trial: 8190572
Drug: Carnitine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (100 mg/kilo)
Trial: 30459160
Drug: Risk-stratified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-stratified treatment approaches in major international cooperative groups
Trial: 30459160
Drug: Current therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapies for infant leukemia
Trial: 22853847
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg/Amlodipine 5 mg (I300/A5)
Trial: 22853847
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg (I300)
Trial: 22853847
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg (I150)
Trial: 20929124
Drug: Astragalus granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus granule (2.25 g twice a day for two weeks)
Trial: 20929124
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for correcting heart failure (including digoxin, diuretics)
Trial: 18761785
Drug: VAL80/HCTZ12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAL80/HCTZ12.5 mg
Trial: 18761785
Drug: VAL80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAL80 mg
Trial: 15834030
Drug: Sildenafil (25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25‐100 mg)
Trial: 7497559
Drug: Caffeine tablets
RxNorm normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine tablets equal to individual average daily caffeine consumption
Trial: 7210779
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of diltiazem (D)
Trial: 7210779
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of nifedipine (N)
Trial: 11856083
Drug: Topical mononitrate
RxNorm normalized name: Thiamine Mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mononitrate hydrogel (0.2% isosorbide‐5‐mononitrate), applied twice daily for 3 weeks
Trial: 11856083
Drug: Topical mononitrate
RxNorm normalized name: Thiamine Mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mononitrate hydrogel
Trial: 10667099
Drug: Treatment A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: 20 MUI of penicillin G per day for 3 weeks, infused over 4 hours
Trial: 10667099
Drug: Treatment B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: 30 MUI of penicillin G per day for 10 days, infused over 6 hours
Trial: 7548778
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 100 mg tablet
Trial: 7548778
Drug: Cefpodoxime proxetoxil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetoxil oral solution (2 mg/mL)
Trial: 7548778
Drug: Cefpodoxime proxetoxil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetoxil oral solution (100 mg) with high-fat meal
Trial: 475366
Drug: Cefaclor 1000
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor 1000 mg
Trial: 475366
Drug: CGP 9000
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 9000 1000 mg
Trial: 475366
Drug: Cephalexin 1000
RxNorm normalized name: cephalexin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 1000 mg (empty stomach)